+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
AJANTPHARM

Ajanta Pharma Share Price

₹3,718.20 +45.4 (1.24%)
New 52W High today

17 Aug, 2026 3:54 PM (IST)

Ajanta Pharma live price: ₹3,718.20. It opened at ₹3,691 vs previous close ₹3,673; intraday high/low: ₹3,738/₹3,650. The 50 & 200 DMA stand at ₹3,369.60/₹3,029.10.

Ajanta Pharma Performance

  • Today's Low
  • ₹3,650
  • Today's High
  • ₹3,738
  • 52 Week Low
  • ₹2,330
  • 52 Week High
  • ₹3,738
  • Open Price₹3,691
  • Previous Close₹3,673
  • Volume152,620
  • 50 DMA₹3,369.60
  • 100 DMA₹3,210.50
  • 200 DMA₹3,029.10

Ajanta Pharma Chart

Investment Returns

  • Over 1 Month + 7.69%
  • Over 3 Month + 17.03%
  • Over 6 Month + 26.47%
  • Over 1 Year + 38.43%

Smart Investing Starts Here Start SIP with Ajanta Pharma for Steady Growth!

Invest Now

Ajanta Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.9
  • PEG Ratio
  • 1.9
  • Market Cap Cr
  • 46,462
  • P/B Ratio
  • 10.3
  • Average True Range
  • 96.5
  • EPS
  • 90.8
  • Dividend Yield
  • 1.6
  • MACD Signal
  • 79.7
  • RSI
  • 72.06
  • MFI
  • 75.33

Latest Stock News Updates

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee Ravi Agrawal Trust

Ajanta Pharma Ltd - 532331 - Participation In Investor Conference

Pls find enclosed Intimation w.r.t participation in Investor Conference

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Pls find enclosed herewith Earning Call Transcript

Ajanta Pharma Financials

Ajanta Pharma Technicals

EMA & SMA

Current Price
₹3,718.20
+ 45.4 (1.24%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹3,508.10
  • 50 Day
  • ₹3,369.60
  • 100 Day
  • ₹3,210.50
  • 200 Day
  • ₹3,029.10

Resistance and Support

3702.07 Pivot Speed
  • R3 3,842.10
  • R2 3,790.10
  • R1 3,754.10
  • S1 3,666.10
  • S2 3,614.10
  • S3 3,578.10

Ajanta Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-30 Quarterly Results & Interim Dividend
2026-05-05 Audited Results
2026-01-30 Quarterly Results
2025-11-03 Quarterly Results & Interim Dividend
2025-07-28 Quarterly Results & Others To consider other business matters.
Date Purpose Remarks
2026-08-05 INTERIM Rs.32.00 per share(1600%)First Interim Dividend
2025-11-10 INTERIM Rs.28.00 per share(1400%)First Interim Dividend
2024-11-06 INTERIM Rs.28.00 per share(1400%)First Interim Dividend
2024-02-08 INTERIM Rs.26.00 per share(1300%)Second Interim Dividend
2023-08-04 INTERIM Rs.10.00 per share(500%)First Interim Dividend
View Ajanta Pharma Dividend History Arrow
Date Purpose Remarks
2012-08-10 Split
Date Purpose Remarks
2022-06-23 Bonus Bonus issue in the ratio of 1:2 of Rs. 2/-.

Ajanta Pharma Shareholding Pattern

63.48%
18.1%
7.68%
7.03%
3.7%

About Ajanta Pharma

Ajanta Pharma is primarily involved in development manufacturing and marketing of speciality pharmaceutical finished dosages.(Source : AR-PDF:202603-01 Pg No:109) View More
  • NSE Symbol
  • AJANTPHARM
  • BSE Symbol
  • 532331
  • ISIN
  • INE031B01049

Similar Stocks to Ajanta Pharma

Ajanta Pharma FAQs

Ajanta Pharma share price is ₹3,718 As on 17 August, 2026 | 23:19

The Market Cap of Ajanta Pharma is ₹46462.3 Cr As on 17 August, 2026 | 23:19

The P/E ratio of Ajanta Pharma is 40.9 As on 17 August, 2026 | 23:19

The PB ratio of Ajanta Pharma is 10.3 As on 17 August, 2026 | 23:19

The 52 week High & Low of Ajanta Pharma is ₹3738/₹2329.9 respectively As on 17 August, 2026 | 23:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23